Menu
Sign In Pricing Add Podcast

BackTable Urology

Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1554.68 - 1570.388 Dr. Andrea Apolo

The question that I think comes up is what is the role now of adjuvant immunotherapy now that we have the Niagara data, right? So how does that fit in? I mean, if everyone's going to be getting Dervalium-AV plus Gem-Sys in the neoadjuvant setting,

0
💬 0

Comments

There are no comments yet.

Log in to comment.